Related Experiment Video
Updated: May 7, 2026
10:26
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Association between polymorphism of beta3-adrenoceptor gene and overactive bladder
Kazuya Honda1, Osamu Yamaguchi, Masanori Nomiya
1Ooizumihonda Clinic, Date City, Japan.
Neurourology and Urodynamics
|September 17, 2013
Summary
The Trp64Arg gene variant in beta3-adrenergic receptors (beta3-ARs) is significantly associated with overactive bladder (OAB) syndrome. This finding may contribute to understanding OAB
Area of Science:
- Pharmacogenetics
- Urology
- Genetics
Background:
- Beta3-adrenergic receptors (beta3-ARs) are crucial for detrusor muscle relaxation in the human urinary bladder during urine storage.
- The Trp64Arg polymorphism in the beta3-AR gene has been investigated for its potential role in urological conditions.
Purpose of the Study:
- To investigate the association between the Trp64Arg polymorphism of the beta3-AR gene and the prevalence of overactive bladder (OAB) syndrome.
Main Methods:
- A case-control study was conducted with 100 women diagnosed with OAB and 101 healthy women without OAB.
- Genotyping for the Trp64Arg polymorphism in the beta3-AR gene was performed using hair root samples via polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
Main Results:
- The frequency of the 64Arg variant was significantly higher in women with OAB (47%) compared to controls (22.8%).
- No significant differences in daily micturition frequency, urgency episodes, or urgency incontinence episodes were observed between 64Arg variant carriers and normal gene carriers within the OAB patient group.
Conclusions:
- The Trp64Arg polymorphism in the beta3-AR gene shows a weak but statistically significant association with overactive bladder (OAB) syndrome.
- This genetic variation may represent a contributing factor to the development or susceptibility of OAB.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...